clinical trial · NCT06565078
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
Takeda·—·recruiting·n = 100
Primary Immunodeficiency Diseases (PID)Immune Globulin Subcutaneous (Human), 20% Solution
brief summary
This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID). This survey will conduct in use of medical database called PIDJ2.
started
Feb 17, 2025
primary completion
Jul 31, 2030
completion
Jul 31, 2030
last updated
Feb 20, 2026
official title
Post-marketing Database Survey: A Cohort Study to Evaluate the Safety of Cuvitru in Patients With Primary Immunodeficiency Using the PIDJ2 (Primary Immunodeficiency Database in Japan) Registry
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol